Inozyme brings $67M to the bank to build up its calcification-focused rare disease pipeline
Inozyme founder Axel Bolte is intensifying his faith in his rare-disease upstart’s lead experimental drug by testing it for a second indication focused on disorders …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.